ReviewiScience2025
From skin lesions to multi-organ involvement: Organ tropism and pathogenesis of mpox virus.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Drivers of Viral Spillover: An Examination of How Pathogens Spread.Pathogens (Basel, Switzerland) · 2026Review
- MPXV H3L elicits broadly directed CD4 T cell responses in mpox patients and MVA vaccinees.Npj viruses · 2026Article
- A Global Health Alert on the Re-Emergence of Mpox a Viral Zoonotic Illness Its Prevention and Management: A Narrative Review.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mpox virus (MPXV), the causative agent of mpox, is a re-emerging zoonotic orthopoxvirus. Until 2022, infections were largely confined to endemic regions in Central and West Africa. However, following phylogenetic divergence and a subsequent global outbreak in 2022 caused by clade IIb, distinct from the clade I-driven resurgence in the Democratic Republic of the Congo in 2024, MPXV has emerged as a significant global health concern. While mpox is primarily characterized by its distinctive skin lesions, growing clinical and experimental evidence suggests that MPXV can replicate and disseminate to further organ systems, potentially contributing to disease severity. Despite this growing knowledge, the mechanisms underlying MPXV organ tropism and pathogenesis remain poorly understood, posing ongoing challenges for research and clinical management. This review summarizes the latest clinical, pathological, and experimental findings to provide an updated understanding of MPXV tropism and pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.